Pacific Biosciences Of California (PACB) Current Deferred Revenue (2010 - 2026)

Pacific Biosciences Of California's Current Deferred Revenue history runs 17 years deep, the most recent figure standing at $16.3 million for Q1 2026.

• On a quarterly basis, Current Deferred Revenue rose 7.15% year-over-year to $16.3 million in Q1 2026; TTM through Mar 2026 was $16.3 million, a 7.15% increase from a year earlier, with the FY2025 full-year figure at $15.9 million, up 14.95% from the prior year.
• Current Deferred Revenue improved to $16.3 million in Q1 2026 per PACB's latest filing, from $15.9 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $32.7 million in Q1 2023 and bottomed at $12.7 million in Q1 2022.
• The 5-year median for Current Deferred Revenue is $22.4 million (2023), against an average of $21.5 million.
• Across the five-year window, Current Deferred Revenue surged 236.52% in 2022 and slumped 46.42% in 2023, its largest moves.
• Year by year, Current Deferred Revenue stood at $30.5 million in 2022, then slumped by 46.42% to $16.3 million in 2023, then decreased by 15.16% to $13.9 million in 2024, then rose by 14.95% to $15.9 million in 2025, then rose by 2.47% to $16.3 million in 2026.
• Per Business Quant, the three latest PACB Current Deferred Revenue figures stand at $16.3 million (Q1 2026), $15.9 million (Q4 2025), and $16.0 million (Q3 2025).